Share |

Verisante Enters Licensing Agreement For Multi Spectral Imaging Technology To Detect Skin Cancer And Oral Cancer

July 12, 2011 at 2:00 pm

Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer imaging technology, is pleased to announce that it has entered into an agreement to license the exclusive world-wide rights for a novel rapid multi-spectral imaging cancer detection technology with the inventors, Dr. Haishan Zeng and Dr. Yasser Fawzy of the British Columbia Cancer Agency.

The rapid multi-spectral imaging technology is protected by a pending patent. The Company has the field of use rights to detect skin cancer and oral cancer, and the right of first refusal for all other cancers.

The technology has the potential to become the best in class modality for field imaging for the localization of cancerous lesions in the epithelial layer of tissue in various body sites. Over the past 11 months, Verisante has acquired the rights to a broad portfolio of over 24 patents, and pending patents, for cancer detection, including white light reflectance imaging, fluorescence imaging, rapid Raman spectroscopy, and rapid multi-spectral imaging.

"By combining different modalities we can increase the sensitivity and specificity of our devices, and ensure the longevity of our product life cycle by continually introducing new technologies", said CEO Thomas Braun. "Once we introduce our Verisante Aura™ product for skin cancer detection we intend to remain the best in class through continuous improvement and acquisition of the latest cutting edge technologies. With our first mover advantage we stand to dominate the market for skin cancer detection by introducing a game changing product, the Verisante Aura™, and with our acquisitive nature we expect to keep our leading position."

The rapid multi-spectral imaging has the potential, as a stand alone product, to be a very low cost solution for skin and oral cancer detection that may prove to be more suitable for the primary care physician or general dentist who may not have the patient base to justify the higher cost of the rapid Raman system.

Verisante Aura™ is a non-invasive device that can be used to detect skin cancer including melanoma, basel cell carcinoma and squamous cell carcinoma instantly, providing immediate and accurate results­­­The Aura™ and other Verisante devices for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians' immediate results for many of the most common cancers. The Aura and Core have not yet been approved for sale. The Company anticipates Health Canada approval for the Aura in late 2011.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information contact:

Verisante Technology, Inc.
Thomas Braun, President & CEO
Telephone: (604) 605-0507


Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top